Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is expected to continue delivering steady growth in its clinical services business, particularly through its faster-growing NGS segment, with potential upside from new test launches such as MRD and liquid profiling. Furthermore, the company has strong potential for margin expansion and significant cash flow improvement. With its position as a key player in the community channel for cancer care and a low valuation of <2x EV/2026 revenue, NeoGenomics presents an attractive investment opportunity. The company is also continuously expanding its test menu with innovative assays, which could lead to sustained revenue growth and a higher stock valuation.

Bears say

NeoGenomics is highly exposed to market share loss as private sophisticated lab competitors are gaining share through improved leverage of patient data and complex NGS reports that are replacing more of its clinical testing volume than anticipated. Furthermore, risks to the Medical and Life Science Tools sector may also negatively impact NEO, including reduced research and development budgets and government funding, decreased purchasing from healthcare/hospital customers, increased regulatory hurdles, and macroeconomic challenges. NEO also faces risks specific to its company, such as potential setbacks in RaDaR reimbursement or patent litigation, greater reinvestment leading to weaker EBITDA margins, negative changes to reimbursement, and the potential for losing market share to more focused competitors.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.